Macrogenics (MGNX) Tax Provisions (2024 - 2025)
Macrogenics (MGNX) posted quarterly Tax Provisions of -$805000.0 for Q4 2025, down 185.28% year-over-year from $944000.0 in Q4 2024, and down 866.67% quarter-over-quarter from $105000.0 in Q2 2025.
Powered by 
Analysis
Macrogenics (MGNX) Tax Provisions (2024 - 2025) Analysis & Trends
Macrogenics (MGNX) has reported Tax Provisions for 2 consecutive years, with -$805000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Tax Provisions fell 185.28% year-over-year to -$805000.0; the TTM figure through Dec 2025 stood at $244000.0 (changed N/A YoY), while the FY2025 annual figure was -$700000.0, down 174.15% from the prior year.
- Tax Provisions retreated to -$805000.0 in Q4 2025 per MGNX's latest filing, from $105000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $944000.0 in Q4 2024 and bottomed at -$805000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Macrogenics | 279.50 Mn | 165.59 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -805,000.00 |
| Jun 30, 2025 | 105,000.00 |
| Dec 31, 2024 | 944,000.00 |